Share This

Public company info - Hong Kong Life Sciences and Technologies Group Ltd. , 08085.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Hong Kong Life Sciences and Technologies Group Ltd., 08085.HK - Company Profile
Chairman -
Share Issued (share) 5,688,000,000
Par Currency Hong Kong Dollar
Par Value 0.04
Industry Biotechnology
Corporate Profile Business Summary: The Group is principally engaged in (i) anti-aging and stem cell technology businesses; (ii) trading business; (iii) money lending business; and (iv) securities investment business. Performance for the year: During the Year, the Group’s total revenue increased by 28.3% to approximately HK$127.5 million (2019: HK$99.4 million) as compared to last year. The loss for the Year was approximately HK$219.5 million (2019: HK$23.3 million) and the loss for the Year attributable to owners of the Company was approximately HK$219.5 million (2019: HK$23.2 million). Business Review： Anti-Aging and Stem Cell Technology Businesses As at 31 March 2020, the Group operated an anti-aging service centre and a stem cell processing centre in Hong Kong and an antiaging and beauty centre in Shenzhen was disposed on 6 May 2019. During the Year, the Group’s revenue from the anti-aging and stem cell technology businesses in Hong Kong was approximately 0.1 million (2019: HK$0.3 million) and the anti-aging and beauty centre in Shenzhen did not contribute any revenue (2019: HK$2.5 million). The segment loss before impairment loss, finance cost and tax expenses were approximately HK$29.5 million (2019: HK$15.9 million). The loss was incurred mainly from the staff and related cost, short-term leases expenses, depreciation of property, plant and equipment and depreciation of right-of-use assets. Trading of Electronic Components During the Year, the Group’s revenue from trading of electronic components in the PRC increased by approximately HK$37.5 million to HK$113.8 million (2019: HK$76.3 million). The increase in revenue was mainly due to no revenue recorded during the first six months ended 30 September 2018. Trading of Healthcare and Personal Care Products The Group has conducted the trading of healthcare and personal care products in Hong Kong since March 2019. During the Year, the Group recorded a revenue of approximately HK$0.9 million (2019: HK$0.5 million). The Group has been sourcing suitable healthcare products which complement the Group’s anti-aging and stem cell technology businesses. The Group will continue to attempt to broaden the customer base and diversify the Group’s trading products to increase its revenue stream and improve the financial performance. The Group will pay close attention to the market situations and make necessary adjustments to the Group’s strategies and operations. Money Lending Business The Group commenced its money lending business through Asia Honest Finance Limited (“Asia Honest”), a direct wholly-owned subsidiary of the Company, which holds a money lenders licence under the Money Lenders Ordinance (Cap. 163, Laws of Hong Kong). As at 31 March 2020, the loan receivables and loan interests receivables (net of impairment loss) amounted to nil (2019: loan receivables of approximately HK$112.2 million and loan interest receivables of approximately HK$5.4 million respectively). During the Year, the Group’s revenue from money lending business decreased by approximately HK$7.0 million to approximately HK$12.7 million (2019: HK$19.7 million). The decrease was mainly due to the average balances of loan receivables were less than the previous year. The interest rate charged by the Group to customers ranging from 10% to 14% for the Year (2019: 10% to 14%) per annum. Securities Investment Business As at 31 March 2020, the Company had held-for-trading investments in the listed company in Hong Kong of approximately HK$0.2 million (2019: HK$0.8 million). During the Year, the Group did not dispose any held-for-trading investment (2019: loss of disposal of approximately HK$0.3 million) and the unrealised loss of held-fortrading investments was approximately HK$0.7 million (2019: HK$3.1 million) representing the fair value change on held-for-trading investments. The Board will continue to monitor the market conditions and its performance. Investment Properties In June 2017, the Group acquired the investment properties situated at Lantau Island, Hong Kong (the “Property”) which is mainly designated for the development of private house for sale. The Property being all those pieces or parcels of ground registered in the Land Registry as LOTS NOS. 484, 489, 491, 492, 493, 530, 533, 535, 550, 553, 556, 571, 574, 608, 612, 615, 618, 619, 623, 625 AND 644 ALL IN DEMARCATION DISTRICT NO. 311 TOGETHER with the messages erections and buildings thereon (if any). Prospects: The Board continues their optimistic outlook of the anti-aging and stem cell technology businesses and will adjust the Group’s development strategy according to the market changes. In this regard, the Group will closely monitor its cash position and constantly keep reviewing its strategies and operations with a view to improving its business performance. The Group remains cautiously proactive about the Group’s future plans to support the Group’s future performance and enhance the interest of the shareholders of the Company (the “Shareholders”).

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.